A Phase 3 interventional study of trimetazidine in ME/CFS
Recruiting Phase 2,Phase 3 ACTRN12625000095460
Study Description
Evaluating the effectiveness of trimetazidine in treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Study Details
- Registry ID:
- ACTRN12625000095460
- Conditions:
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Phase:
- Phase 2,Phase 3
- Target Enrollment:
- 290 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (2 sites)
-
Barwon Health
GEELONG, Victoria, Australia -
Swinburne University of Technology
Hawthorn, Victoria, Australia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.